 | • レポートコード：MRC2304A117 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、251ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥692,860 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,392,860 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に1,731.97百万ドルであった世界のネオアンチゲン標的療法市場規模が2022年に2,394.27百万ドルに到達し、2027年までにCAGR 38.41％で成長して12,180.56百万ドルへと拡大すると予測しています。当調査資料では、ネオアンチゲン標的療法の世界市場について多角的な視点から分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、対象疾患別（骨がん、大腸がん、婦人科がん、非小細胞肺がん、腎細胞がん）分析、ネオアンチゲン種類別（既成ネオアンチゲン、個別化ネオアンチゲン）分析、免疫療法種類別（DNA/RNAベースワクチン、樹状細胞ワクチン、タンパク質/ペプチドベースワクチン、TILベース治療法）分析、投与経路別（皮内投与、静脈内投与、皮下投与）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめました。なお、当書内の企業情報としては、Aduro Biotech, Inc.、Bavarian Nordic、Caladrius Biosciences、Genocea Biosciences、Gradalis、Immunicum、Immunovative Therapies、Iovance Biotherapeutics、Medigene、Neon Therapeutics、Precision Biologics、Vaxon Biotechなどが掲載されています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のネオアンチゲン標的療法市場規模：対象疾患別 - 骨がんにおける市場規模 - 大腸がんにおける市場規模 - 婦人科がんにおける市場規模 - 非小細胞肺がんにおける市場規模 - 腎細胞がんにおける市場規模 ・世界のネオアンチゲン標的療法市場規模：ネオアンチゲン種類別 - 既成ネオアンチゲンの市場規模 - 個別化ネオアンチゲンの市場規模 ・世界のネオアンチゲン標的療法市場規模：免疫療法種類別 - DNA/RNAベースワクチンの市場規模 - 樹状細胞ワクチンの市場規模 - タンパク質/ペプチドベースワクチンの市場規模 - TILベース治療法の市場規模 ・世界のネオアンチゲン標的療法市場規模：投与経路別 - 皮内投与の市場規模 - 静脈内投与の市場規模 - 皮下投与の市場規模 ・世界のネオアンチゲン標的療法市場規模：地域別 - 南北アメリカのネオアンチゲン標的療法市場規模 アメリカのネオアンチゲン標的療法市場規模 カナダのネオアンチゲン標的療法市場規模 ブラジルのネオアンチゲン標的療法市場規模 ... - アジア太平洋のネオアンチゲン標的療法市場規模 日本のネオアンチゲン標的療法市場規模 中国のネオアンチゲン標的療法市場規模 インドのネオアンチゲン標的療法市場規模 韓国のネオアンチゲン標的療法市場規模 台湾のネオアンチゲン標的療法市場規模 ... - ヨーロッパ/中東/アフリカのネオアンチゲン標的療法市場規模 イギリスのネオアンチゲン標的療法市場規模 ドイツのネオアンチゲン標的療法市場規模 フランスのネオアンチゲン標的療法市場規模 ロシアのネオアンチゲン標的療法市場規模 ... - その他地域のネオアンチゲン標的療法市場規模 ・競争状況 ・企業情報 |
The Global Neoantigen Targeted Therapies Market size was estimated at USD 1,731.97 million in 2021 and expected to reach USD 2,394.27 million in 2022, and is projected to grow at a CAGR 38.41% to reach USD 12,180.56 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Neoantigen Targeted Therapies to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Target Disease Indication, the market was studied across Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-small Cell Lung Cancer, and Renal Cell Carcinoma.
Based on Neoantigens Type, the market was studied across Off-the-shelf Neoantigens and Personalized Neoantigens.
Based on Immunotherapy Type, the market was studied across DNA / RNA-based Vaccines, Dendritic Cell Vaccines, Protein / Peptide-based Vaccines, and TIL-based Therapies.
Based on Route of Administration, the market was studied across Intradermal, Intravenous, and Subcutaneous.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Neoantigen Targeted Therapies market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neoantigen Targeted Therapies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neoantigen Targeted Therapies Market, including Aduro Biotech, Inc., Bavarian Nordic, Caladrius Biosciences, Genocea Biosciences, Gradalis, Immunicum, Immunovative Therapies, Iovance Biotherapeutics, Medigene, Neon Therapeutics, Precision Biologics, and Vaxon Biotech.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Neoantigen Targeted Therapies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neoantigen Targeted Therapies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neoantigen Targeted Therapies Market?
4. What is the competitive strategic window for opportunities in the Global Neoantigen Targeted Therapies Market?
5. What are the technology trends and regulatory frameworks in the Global Neoantigen Targeted Therapies Market?
6. What is the market share of the leading vendors in the Global Neoantigen Targeted Therapies Market?
7. What modes and strategic moves are considered suitable for entering the Global Neoantigen Targeted Therapies Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the popularity of neoantigen targeted therapies
5.1.1.2. Surge in number of cancer patients
5.1.1.3. Increase in the geriatric population across the globe
5.1.1.4. Developing healthcare infrastructure
5.1.2. Restraints
5.1.2.1. Side effects associated with neoantigen targeted therapies
5.1.3. Opportunities
5.1.3.1. Technological advancement in the cancer treatment
5.1.3.2. Increasing government investment such as reimbursement plan
5.1.4. Challenges
5.1.4.1. Challenges of neoantigen identification
5.2. Cumulative Impact of COVID-19
6. Neoantigen Targeted Therapies Market, by Target Disease Indication
6.1. Introduction
6.2. Bone Cancer
6.3. Colorectal Cancer
6.4. Gynecological Cancer
6.5. Non-small Cell Lung Cancer
6.6. Renal Cell Carcinoma
7. Neoantigen Targeted Therapies Market, by Neoantigens Type
7.1. Introduction
7.2. Off-the-shelf Neoantigens
7.3. Personalized Neoantigens
8. Neoantigen Targeted Therapies Market, by Immunotherapy Type
8.1. Introduction
8.2. DNA / RNA-based Vaccines
8.3. Dendritic Cell Vaccines
8.4. Protein / Peptide-based Vaccines
8.5. TIL-based Therapies
9. Neoantigen Targeted Therapies Market, by Route of Administration
9.1. Introduction
9.2. Intradermal
9.3. Intravenous
9.4. Subcutaneous
10. Americas Neoantigen Targeted Therapies Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Neoantigen Targeted Therapies Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Neoantigen Targeted Therapies Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Aduro Biotech, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Bavarian Nordic
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Caladrius Biosciences
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Genocea Biosciences
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Gradalis
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Immunicum
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Immunovative Therapies
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Iovance Biotherapeutics
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Medigene
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Neon Therapeutics
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Precision Biologics
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Vaxon Biotech
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing